triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer
February 2002
The FDA has approved the long-acting form of triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer.
This specific topic you are searching for was not covered in the newsletter. In the process of putting together the newsletters, the editorial staff can only pick a limited number of topics. This forces us to cut topics that are still informative and useful. As an extra service to our subscribers we are offering the Detail-Document.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote